期刊文献+

沙利度胺治疗多发性骨髓瘤及其不良反应的观察 被引量:10

Clinical observation of adverse reactions to thalidomide used for multiple myeloma
原文传递
导出
摘要 了解沙利度胺治疗多发性骨髓瘤时发生的不良反应。方法:观察32例多发性骨髓瘤应用沙利度胺期间不良反应的发生情况。结果:沙利度胺不良反应的总发生率为94%,消化系统不良反应87.5%,神经精神系统不良反应84.4%,其它不良反应有窦缓、逸搏心率、药物热、皮疹、水肿等。结论:不良反应以消化及神经系统的症状最常见,停药及减量可减少不良反应的发生,出现不良反应的原因与剂量大小及个体差异有关。 To observe the side-effects of thalidomide used for multiple myeloma. Method:Thalidomide- induced unwanted effects were analysed in 32 inpatients with multiple myeloma. Results; The occurrence rate of adverse reactions was 94% in all, 87.5% in alimentary system, 84.4% in neuropsychic system,and the others included sinus bradycardia, escape rhythm, drug fever, skin rashes, edema, etc. Conclusion; Thalidomide could cause gastro-intestinal and neuropsychic disturbances, which would disappear or relieve with discontinuation of administration or reduction of dose.
作者 阎金松 郭萍
出处 《药物不良反应杂志》 2003年第2期81-83,共3页 Adverse Drug Reactions Journal
关键词 沙利度胺 治疗 多发性骨髓瘤 药物不良反应 观察 thalidomide multiple myeloma adverse drug reactions
  • 相关文献

参考文献2

二级参考文献9

  • 1[1]Singhal S,Mehta J,Desikan R,et al.Anti-tumor activity of thalidomide in refractory multiple myeloma.N Eng J Med,1999,341:1565-1571.
  • 2[2]Parman T,Wiley MJ,Wells PG,et al.Free radial-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity.Nature Medicine,1999,5:582-585.
  • 3[3]Geitz H,Handt S,Zwingenger K,Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.Immunopharmacology,1996,32:213-221.
  • 4[4]Corral LG,Haslett PAJ,Muller GW,et al.Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol,1999,163:380-386.
  • 5[5]Vacca A,Ribatti D,Presta M,et al.Bone marrow neovascularization,plasma cell angiogenic potential,and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.Blood,1999,13:3064-3073.
  • 6[6]Bellamy W,Richter L,Frutigar Y,et al.Expression of vasular endothelial growth factor and its receptor in hematological malignancies.Cancer Res,1999,59:728-733.
  • 7[7]Haslett PAJ,Corral LG,Albert M,et al.Thalidomide costimulates primary human T lymphocytes,preferentially inducing proliferation,cytokine production,and cytotoxic responses in the CD8+ subset.J Exp Med,1998,187:1885-1892.
  • 8[8]Juliusson G,Celsing F,Turesson Ι,et al.Frequent good partial remission from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.Br J Haematol,2000,109:89-96.
  • 9[9]Kneller A,Raanani P,Hardan I,et al.Therapy with thalidomide in refractory multiple myeloma-the revival of an old drug.Br J Haematol 2000;108:391-393.

共引文献8

同被引文献61

引证文献10

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部